Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Genitourinary 2Breast 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 215Uterine Cervical Neoplasms 144Endometrial Neoplasms 111Fallopian Tube Neoplasms 78Breast Neoplasms 59Carcinoma, Non-Small-Cell Lung 43Colorectal Neoplasms 40Stomach Neoplasms 35Melanoma 31Carcinoma, Renal Cell 29Prostatic Neoplasms 28Neoplasms 28Carcinoma, Ovarian Epithelial 28Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Esophageal Neoplasms 25Neoplasm Metastasis 24Lung Neoplasms 23Urinary Bladder Neoplasms 22Head and Neck Neoplasms 21Colonic Neoplasms 20Vulvar Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 14Uterine Neoplasms 13Small Cell Lung Carcinoma 13Sarcoma 13Rectal Neoplasms 12Peritoneal Neoplasms 12

Interventions

niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hereditary Sensory and Autonomic Neuropathies × Gynecologic × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡